NASDAQ:CERCU Cerecor (CERCU) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free CERCU Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume30,141 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cerecor alerts: Email Address Ad Weiss RatingsProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself About CerecorRead More Ad Weiss RatingsProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself CERCU Stock News HeadlinesSeptember 29, 2022 | npr.orgCircle RoundAugust 10, 2022 | investing.comEDIT, HTGM, NTNX, TWTRJuly 20, 2022 | marketwatch.comDiGeorge Syndrome Drug Market is Expected to Gain Popularity Across the Globe by 2029October 26, 2021 | finance.yahoo.comHedge Funds Are Piling Into Atreca, Inc. (BCEL)October 26, 2021 | finance.yahoo.comDilution Ahead For Cerecor Inc (CERC) Shareholders?October 15, 2021 | bizjournals.comFrom depression to sleep, new era of psychiatric drugs is here, says startup CEOSeptember 22, 2021 | reuters.comAvalo Therapeutics IncJuly 28, 2021 | seekingalpha.comCerecor shares surge 23% on initial results from early-stage CERC-002 Crohn's disease trialJuly 27, 2021 | apnews.comCerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe ...July 26, 2021 | msn.comBRIEF-Cerecor Reports Positive Initial Results for CERC-002 in Moderate to Severe Crohn's Disease PatientsJuly 26, 2021 | marketwatch.comCerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease PatientsSee More Headlines Receive CERCU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerecor and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:CERCU CUSIPN/A CIKN/A WebN/A PhoneN/AFaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:CERCU) was last updated on 5/26/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s PRIME is Set to Shock the WorldInvestorPlaceJust $9 for a Year of Winning Market InsightsBehind the Markets[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaNew Options need New Trading StrategiesNetpicksClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsUrgent Nvidia WarningAltimetryThe Presidential candidate you should REALLY be worried aboutStansberry ResearchDems have chosen Biden replacement?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.